Inovio (INO) Reports Encouraging Data for SynCon Vaccine in Generating HAI Titers

Inovio Pharmaceuticals, Inc. (NYSE: INO) reports that its SynCon avian influenza vaccine generated protective HAI titers against six different unmatched strains of H5N1 in a phase I clinical trial - a distinct clinical achievement on Inovio's path to develop universal influenza vaccines. By design, Inovio's SynCon flu vaccine is not matched to any single virus. Importantly, the vaccine generated a hemagglutination inhibition (HAI) titer of 1:40 or higher against at least one of the six tested H5N1 strains in 8 of 17 (47%) immunized subjects, demonstrating the vaccine's broad coverage; 12 of 17 (71%) vaccines generated an HAI titer of 1:20 or higher, indicating a positive vaccine response, against at least one H5N1 strain.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Kimbell Royalty closes $221.2M mineral rights acquisition
• enVVeno Medical (NVNO) files $100M mixed shelf